N-(Pyridin-3-Yl)-4-(3-((5-(Trifluoromethyl)Pyridin-2-Yl)Oxy)Benzyl)Piperidine-1-Carboxamide N-(吡啶-3-基)-4-(3-((5-(三氟甲基)吡啶-2-基)氧基)苄基)哌啶-1-酰胺
CAS 1196109-52-0 MFCD21365072
化学结构图
SMILES: O=C(Nc1cccnc1)N1CCC(Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1
化学属性
| Mol. Weight | 456 |
|---|---|
| Mol. Formula | C24H23F3N4O2 |
| Appearance | Solid powder |
| Solubility | Soluble in DMSO, not soluble in water. |
别名和识别编码
| Synonym | N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide hydrate PF3845; PF-3845; PF 3845. |
|---|---|
| MDL Number | MFCD21365072 |
| CAS Number | 1196109-52-0 |
| Chemical Name | N-(Pyridin-3-Yl)-4-(3-((5-(Trifluoromethyl)Pyridin-2-Yl)Oxy)Benzyl)Piperidine-1-Carboxamide |
| PubChem Substance ID | 329823740 |
| Chemical Name Translation | N-(吡啶-3-基)-4-(3-((5-(三氟甲基)吡啶-2-基)氧基)苄基)哌啶-1-酰胺 |
| Formula | C24H23F3N4O2 |
| IUPAC Name | N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide |
| InChIKey | NBOJHRYUGLRASX-UHFFFAOYSA-N |
| InChI | InChI=1S/C24H23F3N4O2/c25-24(26,27)19-6-7-22(29-15-19)33-21-5-1-3-18(14-21)13-17-8-11-31(12-9-17)23(32)30-20-4-2-10-28-16-20/h1-7,10,14-17H,8-9,11-13H2,(H,30,32) |
| Canonical SMILES | O=C(N1CCC(CC2=CC=CC(OC3=NC=C(C(F)(F)F)C=C3)=C2)CC1)NC4=CC=CN=C4 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cannabinoids, Cell Biology, Cell Signaling and Neuroscience, Enzyme Inhibitors, Fatty Acid Amide Hydrolase, Neurobiology, Neuroscience, Neurotransmission, Neurotransmitter Metabolism, P, Pfizer Compounds, Pharmacologicals
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Cannabinoids, Diversification Ready Pharma-Developed Compounds, Enzyme Inhibitors, Fatty Acid Amide Hydrolase, Neurobiology, Neuroscience, Neurotransmission, Neurotransmitter Metabolism,
产品应用
- PF-3845 is a fatty acid amide hydrolase (FAAH) inhibitor, and acts in the nervous system to reverse LPS-induced tactile allodynia in mice. PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Treatment with PF3845 inactivated FAAH activity and enhanced the AEA levels in the brain. It reduced neurodegeneration in the dentate gyrus, and up-regulated the expression of Bcl-2 and Hsp70/72 in both cortex and hippocampus. PF3845 also suppressed the increased production of amyloid precursor protein, prevented dendritic loss and restored the levels of synaptophysin in the ipsilateral dentate gyrus.
相关文献及参考
- [2]. Wasilewski A, et, al. Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study. Acta Biochim Pol. 2017;64(3):519-525.
- [3]. Booker L, et al. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol, 2012, 165(8), 2485-2496.
- K Ahn, DS Johnson, M Mileni, D Beidler, JZ Long, et al., Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chemistry and Biology 16 , 411-20, (2009)
- Long JZ, LaCava M, Jin X, Cravatt BF., An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase. J. Lipid Res. 2 , 337-44, (2011)
- [1]. Ahn K, et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol. 2009 Apr 24;16(4):411-20.
- {MCE
安全信息
GHS Symbol
- P301+P310
- H301 Toxic if swallowed 吞食有毒
- S45 In case of accident or if you feel unwell seek medical advice immediately (show the label where possible) 发生事故时或感觉不适时，立即求医（可能时出示标签）；
- R25 Toxic if swallowed 吞咽有毒
